Author: UW CTI

Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer....

Clinical trials represent a critical path to innovative treatments, life-changing cures, and medical progress. But for all their scientific rigor, most trials fail to include one crucial element: input from the very people they aim to help....

After more than a decade studying a rare eye cancer that produces some of the hardest-to-fight tumors, researchers from University of Pittsburgh Medical Center have found a treatment that works on some patients and, more importantly, a tool that can predict when it is likely...

Wisconsin's recent federal designation as a Regional Tech Hub is an achievement made possible by countless professionals whose vision and commitment to excellence are part of the history of the University of Wisconsin School of Medicine and Public Health....